logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
08/02/2026
Pai Jie Securities raised Cisco's target price from $70 to $86.
Latest
3 m ago
Winter storms keep coming, Spain and Portugal are severely affected.
6 m ago
According to the AI Fast News of Every Economic News, Huayuan Securities released a research report on February 8th, giving a "buy" rating to Xinrui Dairy (002946.SZ). The reasons for the rating mainly include: 1) Xinrui Dairy has achieved national layout and strategic transformation through multiple rounds of mergers and acquisitions; 2) Xinrui Dairy has advantages in the low-temperature milk market with great growth potential in the future; 3) Xinrui Dairy's DTC channel and expansion into the sinking market are expected to help drive performance growth. (Every Economic News)
7 m ago
Every Economy AI Flash, Pacific Securities released a research report on February 8th, giving a "buy" rating to Korui International (300662.SZ). The rating reasons mainly include: 1) From the median of the forecast, the core operating profit growth rate of Q4 has slowed slightly; 2) Main business is stable, structural optimization; 3) Overseas business has successfully reversed losses; 4) The core AI strategy "HeWa" platform is growing rapidly. (Daily Economic News)
8 m ago
On February 7th, the total social inter-regional personnel flow reached 22.251 million people.
9 m ago
Every Investment AI Flash, Open Source Securities released a research report on February 7, giving DeYuan Pharmaceutical (920735.SH) a "buy" rating. The reasons for the rating include: 1) full efforts to expand the market, sales of "Fu Rutong" and "Bo Kaiqing" increasing, supplying the tenth batch of centralized procurement products; 2) by 2025, obtaining registration approvals for 8 varieties of drugs, with the adaptation indication of DYX116 for hypoglycemia undergoing phase I clinical trials. (Daily Economic News)
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.